Adding ascorbic acid to arsenic trioxide produces limited benefit in patients with acute myeloid leukemia excluding acute promyelocytic leukemia
Authors:
- 7 June 2014
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 93 (11) , 1839-1843
Abstract
Arsenic trioxide (ATO) is highly effective in acute promyelocytic leukemia (APL), but despite its multiple mechanism of action, it has no activity in acute myeloid leukemia (AML) that excludes APL (non-APL AML). Ascorbic acid (AA) and ATO induces apoptosis in AML cell lines by depleting intracellular glutathione and generation of reactive oxygen species. In this study, we evaluated the effect of ATO plus AA in patients with non-APL AML. The study enrolled patient aged 18 or older with relapsed or refractory AML (non-APL) after conventional chemotherapy or previously untreated patients 55 years or older who were unfit for standard induction chemotherapy for AML. Intravenous ATO (0.25 mg/kg/day over 1–4 h) was given with intravenous AA (1 g/day over 30 min after ATO) for 5 days a week for 5 weeks (25 doses). Eleven AML patients were enrolled, including six previously untreated elderly patients aged 66–84 years in whom five had antecedent hematological disorder (ADH). Among 10 evaluable patients, one achieved a CR one a CRi and 4 patients had disappearance of blasts from peripheral blood and bone marrow. Five of the six responders were seen in previously untreated elderly patients. ATO related toxicity was mild. The combination of ATO and AA has limited clinical meaningful antileukemia activity in patients with non-APL AML.Keywords
This publication has 23 references indexed in Scilit:
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic LeukemiaNew England Journal of Medicine, 2013
- Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicityBlood, 2006
- Arsenic Trioxide Therapy in Relapsed or Refractory Japanese Patients with Acute Promyelocytic Leukemia: Updated Outcomes of the Phase II Study and Postremission TherapiesInternational Journal of Hematology, 2005
- Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic MalignanciesJournal of Clinical Oncology, 2005
- United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic LeukemiaJournal of Clinical Oncology, 2001
- Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xLBlood, 2000
- Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemiaLeukemia, 2000
- Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitroFEBS Letters, 1999
- The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasmsLeukemia, 1998
- Arsenic induces apoptosis in B‐cell leukaemic cell lines in vitro: activation of caspases and down‐regulation of Bcl‐2 proteinBritish Journal of Haematology, 1998